ZA201105437B - Biomarkers for inhibitors with anti-angiogenic activity - Google Patents

Biomarkers for inhibitors with anti-angiogenic activity

Info

Publication number
ZA201105437B
ZA201105437B ZA2011/05437A ZA201105437A ZA201105437B ZA 201105437 B ZA201105437 B ZA 201105437B ZA 2011/05437 A ZA2011/05437 A ZA 2011/05437A ZA 201105437 A ZA201105437 A ZA 201105437A ZA 201105437 B ZA201105437 B ZA 201105437B
Authority
ZA
South Africa
Prior art keywords
biomarkers
inhibitors
angiogenic activity
angiogenic
activity
Prior art date
Application number
ZA2011/05437A
Other languages
English (en)
Inventor
Joyce Behrens
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA201105437B publication Critical patent/ZA201105437B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ZA2011/05437A 2008-12-23 2011-07-22 Biomarkers for inhibitors with anti-angiogenic activity ZA201105437B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08022436 2008-12-23
PCT/EP2009/008929 WO2010072348A1 (fr) 2008-12-23 2009-12-14 Biomarqueurs pour inhibiteurs ayant une activité antiangiogénique

Publications (1)

Publication Number Publication Date
ZA201105437B true ZA201105437B (en) 2012-03-28

Family

ID=41666642

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/05437A ZA201105437B (en) 2008-12-23 2011-07-22 Biomarkers for inhibitors with anti-angiogenic activity

Country Status (15)

Country Link
US (1) US20120004129A1 (fr)
EP (2) EP2368118B1 (fr)
JP (1) JP5680547B2 (fr)
KR (1) KR101717304B1 (fr)
CN (1) CN102265156B (fr)
AU (1) AU2009331955B2 (fr)
CA (1) CA2747937C (fr)
DK (1) DK2368118T3 (fr)
EA (1) EA020764B1 (fr)
ES (1) ES2440565T3 (fr)
MX (1) MX2011006675A (fr)
PL (1) PL2368118T3 (fr)
PT (1) PT2368118E (fr)
WO (1) WO2010072348A1 (fr)
ZA (1) ZA201105437B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646160A (zh) 2002-03-13 2005-07-27 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
CA2648385C (fr) 2006-04-04 2020-09-01 Singulex, Inc. Systeme et procedes hautement sensibles destines a une analyse de la troponine
JP5678045B2 (ja) 2009-06-08 2015-02-25 シンギュレックス・インコーポレイテッド 高感度バイオマーカーパネル
US8759298B2 (en) 2010-05-03 2014-06-24 Scott & White Healthcare Protein therapy for corneal inflammation, epithelial wound healing, and photoreceptor degeneration
WO2012107211A1 (fr) 2011-02-11 2012-08-16 Merck Patent Gmbh Anticorps anti-alpha-v intégrine pour le traitement du cancer de la prostate
BR112013031019A2 (pt) 2011-06-02 2017-03-21 Almac Diagnostics Ltd teste diagnóstico molecular para câncer
HK1208470A1 (en) * 2012-03-29 2016-03-04 Biogen Ma Inc. Biomarkers for use in integrin therapy applications
MX2015006955A (es) 2012-12-03 2016-01-25 Almac Diagnostics Ltd Prueba de diagnostico molecular para cancer.
CN103083686B (zh) * 2013-02-18 2014-09-10 上海交通大学医学院附属仁济医院 Dkk4基因及其编码蛋白在制备药物中的应用
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
WO2014143739A2 (fr) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anticorps anti-alpha ν bêta 6 et leurs utilisations
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
EP3194972B1 (fr) * 2014-09-17 2021-04-14 Merck Patent GmbH Méthode de traitement de maladies provoquées par des métastases osseuses, médicaments à cet effet, et méthode de prédiction du résultat clinique du traitement de maladies provoquées par des métastases osseuses
ES2856348T3 (es) * 2014-09-17 2021-09-27 Merck Patent Gmbh Un método para el tratamiento de cánceres sólidos y/o metástasis de los mismos, medicamentos relacionados, y un método para la predicción de la evolución clínica del tratamiento de cánceres sólidos y/o metástasis de los mismos
KR101751929B1 (ko) * 2015-01-05 2017-06-28 서울대학교 산학협력단 신규 간암 환자의 소라페닙 저항성 예측 마커
US10510144B2 (en) 2015-09-10 2019-12-17 Magentiq Eye Ltd. System and method for detection of suspicious tissue regions in an endoscopic procedure
EP3364190A1 (fr) * 2017-02-20 2018-08-22 Panka Cancer Research AG Procédé de détection du cancer ou de cellules cancéreuses
WO2019072888A1 (fr) * 2017-10-11 2019-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de prédiction de la réponse thérapeutique dans le cancer hépatocellulaire
KR20210038893A (ko) * 2018-07-31 2021-04-08 에프. 호프만-라 로슈 아게 심방 세동의 평가에서 순환하는 dkk3(딕오프 관련 단백질 3)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
DE69531187T2 (de) 1994-12-20 2004-04-22 Merck Patent Gmbh Monoklonaler Antikörper gegen das Alpha-V-Integrin
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US6521593B1 (en) 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
HUP0302718A3 (en) 2000-11-01 2011-03-28 Merck Patent Gmbh Methods and compositions for the treatment of diseases of the eye
GB0202881D0 (en) * 2002-02-07 2002-03-27 Univ Cambridge Tech Improvements relating to diagnostics
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
CN1977049A (zh) * 2004-04-26 2007-06-06 儿童医疗中心有限公司 用于检测疾病的血小板生物标志物
MX2007001357A (es) * 2004-08-02 2009-08-07 Childrens Medical Center Biomarcadores de plaquetas para cancer.
BRPI0518105A (pt) * 2004-12-17 2008-11-04 Genentech Inc uso de antagonista da angiogênese e uso de anticorpo anti-vegf
US20080306002A1 (en) * 2005-08-18 2008-12-11 The General Hospital Corporation Combination Therapy for Preventing Angiogenesis
US8158107B2 (en) * 2005-09-30 2012-04-17 National Jewish Health Genes and proteins associated with angiogenesis and uses thereof
DK2167128T3 (da) 2007-07-17 2012-12-03 Merck Patent Gmbh Fremstillede anti-alfa-v-integrin hybrid-antistoffer

Also Published As

Publication number Publication date
KR20110116021A (ko) 2011-10-24
JP2012513422A (ja) 2012-06-14
WO2010072348A1 (fr) 2010-07-01
MX2011006675A (es) 2011-07-12
PL2368118T3 (pl) 2014-03-31
US20120004129A1 (en) 2012-01-05
CN102265156A (zh) 2011-11-30
JP5680547B2 (ja) 2015-03-04
DK2368118T3 (da) 2013-11-25
KR101717304B1 (ko) 2017-03-16
EP2706358A2 (fr) 2014-03-12
AU2009331955B2 (en) 2015-09-24
CN102265156B (zh) 2014-11-05
EP2368118B1 (fr) 2013-10-16
AU2009331955A1 (en) 2011-08-04
EP2706358A3 (fr) 2014-05-07
EP2368118A1 (fr) 2011-09-28
EA020764B1 (ru) 2015-01-30
CA2747937C (fr) 2019-02-26
CA2747937A1 (fr) 2010-07-01
PT2368118E (pt) 2014-01-13
EA201100965A1 (ru) 2012-05-30
ES2440565T3 (es) 2014-01-29

Similar Documents

Publication Publication Date Title
ZA201105437B (en) Biomarkers for inhibitors with anti-angiogenic activity
HUS2000024I1 (hu) Béta laktamáz inhibitorok
ZA201100898B (en) Novel inhibitors
IL238583B (en) 2-acylaminopropanol-like as glucosylceramide synthase inhibitors
GB201102702D0 (en) Predictive biomarkers
GB0818660D0 (en) Biomarkers
ZA201105184B (en) Biomarker
GB0807214D0 (en) Biomarkers
ZA201102837B (en) Phosphodiestarase inhibitors
ZA201102179B (en) Protease inhibitors
GB0821912D0 (en) Biomarkers
GB0818658D0 (en) Biomarkers
GB0817429D0 (en) Enzyme inhibitors
GB0817425D0 (en) Protease inhibitors
GB201019387D0 (en) Inhibitors
GB0805081D0 (en) Biomarkers
GB0805084D0 (en) Biomarkers
GB0809105D0 (en) Biomarkers
GB0806911D0 (en) Polymerase inhibitors
GB0806915D0 (en) Polymerase inhibitors
GB0806914D0 (en) Polymerase inhibitors
GB0806913D0 (en) Polymerase inhibitors
GB0806912D0 (en) Polymerase inhibitors
GB0806917D0 (en) Polymerase inhibitors
GB0806920D0 (en) Polymerase inhibitors